Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Other Working Capital Changes (2019 - 2023)

Alx Oncology Holdings' Other Working Capital Changes history spans 5 years, with the latest figure at $3.3 million for Q4 2023.

  • For Q4 2023, Other Working Capital Changes rose 171.13% year-over-year to $3.3 million; the TTM value through Dec 2023 reached $1.3 million, down 12.53%, while the annual FY2025 figure was -$1.9 million, 74.1% up from the prior year.
  • Other Working Capital Changes for Q4 2023 was $3.3 million at Alx Oncology Holdings, up from -$4.0 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $3.3 million in Q4 2023 and bottomed at -$4.0 million in Q3 2023.
  • The 5-year median for Other Working Capital Changes is $265500.0 (2021), against an average of $347944.4.
  • The largest YoY upside for Other Working Capital Changes was 592.68% in 2020 against a maximum downside of 7687.5% in 2020.
  • A 5-year view of Other Working Capital Changes shows it stood at -$8000.0 in 2019, then plummeted by 7687.5% to -$623000.0 in 2020, then surged by 35.63% to -$401000.0 in 2021, then surged by 401.5% to $1.2 million in 2022, then skyrocketed by 171.13% to $3.3 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Other Working Capital Changes are $3.3 million (Q4 2023), -$4.0 million (Q3 2023), and $2.2 million (Q2 2023).